UPDATED: You know AAV and LNP. What about PLV? Eli Lilly lines up new vehicle to deliver its genetic medicines
Eli Lilly is beefing up its fleet of vehicles being deployed to carry drugs to the brain.
Enlisting Canada’s Entos Pharmaceuticals, Eli Lilly has grabbed rights to a suite of proteo-lipid vehicles (PLVs) as part of a research collaboration that spans multiple programs focused on diseases of the central and peripheral nervous system. Entos will receive an upfront of $50 million, part of it as an equity investment, to start developing PLVs for Lilly’s selection.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 129,700+ biopharma pros reading Endpoints daily — and it's free.